Tyrosine Kinase 2 Inhibitor Benefits AD in Phase 2 Study

by admin | Jan 14, 2026 | Health

Spread the love

Once-daily oral ICP-332 results in large reduction in eczema scores and shows favorable safety in adults with moderate-to-severe atopic dermatitis.
Medscape Medical News

← Iran protest sparks, China vs India and Russia’s real economy China probes largest online travel agency Trip.com over suspected monopoly →

Written By

Written by Albert Pham, News Curator and Blogger

AI Startup Red Queen Bio Uses Artificial Intelligence to Prepare for a Future Pandemic

Sep 28, 2026 | albertpham, Economy_finances, Health, Technology

Red Queen Bio is using AI to design antibody drugs against novel pathogens, highlighting the growing role of artificial intelligence in pandemic preparedness and biotech.

Harvard, MIT Professors Move to Canada Amid U.S. Research Funding Cuts

Sep 25, 2026 | albertpham, Economy_finances, Health, Politics

Harvard and MIT professors are moving to Canadian universities as Canada invests billions to attract global researchers amid U.S. research funding uncertainty.

Americans Could Lose Access to Cheaper Canadian Prescription Drugs

Sep 22, 2026 | albertpham, Economy_finances, Health

U.S. customs changes could restrict Americans’ access to cheaper prescription drugs from Canada and other foreign pharmacies starting in October.

Tyrosine Kinase 2 Inhibitor Benefits AD in Phase 2 Study

Written By

Related Posts

AI Startup Red Queen Bio Uses Artificial Intelligence to Prepare for a Future Pandemic

Harvard, MIT Professors Move to Canada Amid U.S. Research Funding Cuts

Americans Could Lose Access to Cheaper Canadian Prescription Drugs

0 Comments

Explore More

Connect With Us

Quick Links

Legal

Stay Updated